| Zacks Company Profile for iBio, Inc. (IBIO : NSDQ) |
|
|
| |
| • Company Description |
| Ibio Inc., formerly known as iBioPharma Inc., is a biopharmaceutical company that primarily focuses on developing vaccines and therapeutic proteins based upon its plant-based iBioLaunch platform technology. The Company's hydroponically grown green plants can be used for the development and manufacture of proteins applicable to a range of disease agents, such as influenza, sleeping sickness, anthrax, plague, human papillomavirus and veterinary influenza applications. IBio, Inc. is headquartered in Newark, Delaware.
Number of Employees: 16 |
|
|
| |
| • Price / Volume Information |
| Yesterday's Closing Price: $0.82 |
Daily Weekly Monthly
 |
| 20 Day Moving Average: 5,407,149 shares |
| Shares Outstanding: 16.52 (millions) |
| Market Capitalization: $13.63 (millions) |
| Beta: 0.94 |
| 52 Week High: $6.89 |
| 52 Week Low: $0.64 |
| Short Interest Ratio: |
| |
% Price Change |
% Price Change Relative to S&P 500 |
| 4 Week |
-19.90% |
-22.90% |
| 12 Week |
-7.29% |
-22.02% |
| Year To Date |
-66.33% |
-68.46% |
|
|
|
|
| |
| • Address & Contact Information |
| Street Address |
Phone / Fax |
Email Address |
Web URL |
11750 Sorrento Valley Road Suite 200
-
San Diego,CA 92121
USA |
ph: 979-446-0027
fax: 302-356-1173 |
ir@ibioinc.com |
http://www.ibioinc.com |
|
|
| |
| • General Corporate Information |
Officers
Martin Brenner - Chief Executive Officer
William Clark - Chairman
Felipe Duran - Chief Financial Officer
Alexandra Kropotova - Director
Evert Schimmelpennink - Director
|
|
Peer Information
iBio, Inc. (CORR.)
iBio, Inc. (RSPI)
iBio, Inc. (CGXP)
iBio, Inc. (BGEN)
iBio, Inc. (GTBP)
iBio, Inc. (RGRX)
|
|
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 451033708
SIC: 2834
|
|
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: 03/01/25
Next Expected EPS Date: 09/19/25
|
|
Share - Related Items
Shares Outstanding: 16.52
Most Recent Split Date: 11.00 (0.05:1)
Beta: 0.94
Market Capitalization: $13.63 (millions)
|
|
|
|
|
| |
| • EPS Information |
• Dividend Information |
| Analyst Coverage: No |
Dividend Yield: 0.00% |
| Current Fiscal Quarter EPS Consensus Estimate: $ |
Indicated Annual Dividend: $0.00 |
| Current Fiscal Year EPS Consensus Estimate: $-0.82 |
Payout Ratio: |
| Number of Estimates in the Fiscal Year Consensus: 1.00 |
Change In Payout Ratio: |
| Estmated Long-Term EPS Growth Rate: % |
Last Dividend Paid: NA - $0.00 |
| Next EPS Report Date: 09/19/25 |
|
|
|
| |
